Mihnea graduated from the University of Glasgow with a BSc in Neuroscience in June 2015. Major projects in his undergraduate degree included one internship on the identification of metabolites relevant in predicting patients prone to cerebral stroke and another on the effect of hyperglycaemia on stroke outcome. His dissertation was on the development of a method for creating networks of neurons with guided growth. He then pursued an MSc in Drug Discovery and Development at the University of Aberdeen where he tested a combinatorial therapy consisting of a novel silk biomaterial and integrin overactivation for spinal cord regeneration, graduating with Distinction.

Mihnea joined Sonopill in September 2016 as a PhD student working on ultrasound mediated targeted drug delivery. Specifically, he is investigating how to facilitate drug delivery to and through the small intestine of the GI tract. The findings will be implemented in the treatment protocol of SonoCAIT, a minimally invasive capsule based treatment option. SonoCAIT aims to deliver drugs to specific sites, reducing the side effects and increasing drug uptake while treating or curing different diseases. Mihnea’s goal is to advance SonoCAIT to a translational trial stage. His supervisory team comprises Prof. Sandy Cochran (University of Glasgow), Prof. Inke Nathke (University of Dundee), Dr. Helen Mulvana (University of Glasgow), Dr. Maya Thanou (King’s College London) and Mr. Dave Lines (Diagnostic Sonar Ltd).